 |
|
|
|
||||||
|
 |
|
|
||||||
 |
|||||||||
|
|
||||||||
|
|
|
||
|
|
|
||
|
|
|
||
|
 |
|
||
|
Pharmaceuticals: US Products |
|
||
|
|
|
||
|
Consumers: | |
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
FDA APPROVES NEW ONCE-A-MONTH DOSE OF ACTONEL FOR POSTMENOPAUSAL OSTEOPOROSIS | |
||
|
|
|
||
|
CINCINNATI, Bridgewater, NJ, April 24, 2008 — The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of ActonelŽ (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis. More:   |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
|
|
||
|
|||||||
|
|
||||||||||||||||||||
|
|
||||||||||||||||||||
|
|
|
|
|
|||||||||||||||||
|
|
||||||||||||||||||||
